Construct: ORF ccsbBroadEn_04466
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF016955.1_s300c1, BRDN0000386367
- DNA Barcode:
- None
- Epitope Tag:
- None
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- PHYKPL (85007)
Vector Information:
- Vector Backbone:
- pDONR223
- Pol II Cassette 1:
- n/a
- Pol II Cassette 2:
- n/a
- Selection Marker:
- n/a
- Visible Reporter:
- n/a
- Epitope Tag:
- n/a
Current transcripts matched by this ORF:
| Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
|---|---|---|---|---|---|---|---|---|
| 1 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | NM_153373.4 | 100% | 100% | |
| 2 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_011534671.2 | 98.6% | 98.4% | 702_719del |
| 3 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_011534669.2 | 97.8% | 97.6% | 702_731del |
| 4 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | NM_001278346.1 | 90.8% | 90.8% | 0_1ins123 |
| 5 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_006714925.2 | 90.3% | 83.1% | (many diffs) |
| 6 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_017009995.1 | 90.2% | 85% | (many diffs) |
| 7 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_011534672.2 | 88.9% | 88.6% | 0_1ins123;579_608del |
| 8 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_011534670.3 | 87.3% | 81.5% | (many diffs) |
| 9 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446240.1 | 82% | 73.8% | 701_702ins88;838_839ins155 |
| 10 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_017009998.2 | 81.1% | 74.1% | (many diffs) |
| 11 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_011534674.2 | 76.6% | 72.2% | 337_338ins280;421_422ins35 |
| 12 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446241.1 | 70% | 66.5% | 702_731del;956_957ins155;996_997ins229 |
| 13 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956188.1 | 69.7% | (many diffs) | |
| 14 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956186.1 | 68.6% | (many diffs) | |
| 15 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956195.1 | 65.1% | (many diffs) | |
| 16 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956194.1 | 65% | (many diffs) | |
| 17 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446242.1 | 64.9% | 58.7% | (many diffs) |
| 18 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956193.1 | 64.7% | 1_234del;935_936ins88;1497_1862del | |
| 19 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956196.1 | 63.7% | (many diffs) | |
| 20 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956189.1 | 62.7% | (many diffs) | |
| 21 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956192.1 | 61.2% | 1_234del;1160_1161ins155;1430_1795del | |
| 22 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956190.1 | 60.3% | (many diffs) | |
| 23 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | NR_103510.1 | 59.4% | (many diffs) | |
| 24 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446244.1 | 58.6% | 58.6% | 0_1ins558 |
| 25 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_017009999.2 | 57.3% | 57.1% | 0_1ins558;144_173del |
| 26 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446243.1 | 57.3% | 57.1% | 0_1ins558;144_173del |
| 27 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446248.1 | 55.7% | 54.4% | (many diffs) |
| 28 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446249.1 | 55.2% | 54.4% | (many diffs) |
| 29 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446250.1 | 55.2% | 54.4% | (many diffs) |
| 30 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446246.1 | 54.6% | 47.5% | (many diffs) |
| 31 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446247.1 | 54.6% | 47.5% | (many diffs) |
| 32 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446245.1 | 54% | 53% | (many diffs) |
| 33 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446252.1 | 51.9% | 52% | 702_702delAins649 |
| 34 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XM_024446251.1 | 49.8% | 47.7% | (many diffs) |
| 35 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | NR_103508.1 | 44.4% | (many diffs) | |
| 36 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956187.1 | 44.1% | (many diffs) | |
| 37 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | NR_103509.1 | 41% | (many diffs) | |
| 38 | human | 85007 | PHYKPL | 5-phosphohydroxy-L-lysine p... | XR_002956191.1 | 38.8% | (many diffs) | |
| 39 | mouse | 72947 | Phykpl | 5-phosphohydroxy-L-lysine p... | NM_028398.2 | 82.8% | 83.7% | (many diffs) |
| 40 | mouse | 72947 | Phykpl | 5-phosphohydroxy-L-lysine p... | XM_006534325.3 | 82% | 82.8% | (many diffs) |
| 41 | mouse | 72947 | Phykpl | 5-phosphohydroxy-L-lysine p... | XM_006534324.3 | 80.4% | 81.2% | (many diffs) |
| 42 | mouse | 72947 | Phykpl | 5-phosphohydroxy-L-lysine p... | XM_006534323.3 | 79.6% | 80.4% | (many diffs) |
| 43 | mouse | 72947 | Phykpl | 5-phosphohydroxy-L-lysine p... | XM_017314796.1 | 43.8% | 40.5% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 66
- ORF end:
- 1416
- ORF length:
- 1350
- Sequence:
-
1 gttcgttgca acaaattgat gagcaatgct tttttataat gccaaCTTTG TACAAAAAAG 61 TTGGCATGGC CGCAGACCAG CGCCCGAAGG CCGACACGCT GGCCCTGAGG CAACGGCTCA 121 TCAGCTCTTC CTGCAGACTC TTTTTTCCCG AGGATCCTGT TAAGATTGTC CGGGCCCAAG 181 GGCAGTACAT GTACGATGAA CAGGGGGCAG AATACATCGA TTGCATCAGC AATGTGGCGC 241 ACGTTGGGCA CTGCCACCCT CTCGTGGTCC AAGCAGCACA TGAGCAGAAC CAGGTGCTCA 301 ACACCAACAG CCGGTACCTG CATGACAACA TCGTGGACTA TGCGCAGAGG CTGTCAGAGA 361 CCCTGCCGGA GCAGCTCTGT GTGTTCTATT TCCTGAATTC TGGGTCAGAA GCCAATGACC 421 TGGCCCTGAG GCTGGCTCGC CACTACACGG GACACCAGGA CGTGGTGGTA TTAGATCATG 481 CGTATCACGG CCACCTGAGC TCCCTGATTG ACATCAGTCC CTACAAGTTC CGCAACCTGG 541 ATGGCCAGAA GGAGTGGGTC CACGTGGCAC CTCTCCCAGA CACCTACCGG GGCCCCTACC 601 GGGAGGACCA CCCCAACCCA GCTATGGCCT ATGCCAACGA GGTGAAACGT GTGGTCAGCA 661 GTGCACAGGA GAAGGGCAGG AAGATTGCAG CCTTCTTCGC TGAGTCTCTG CCCAGTGTGG 721 GAGGGCAGAT CATTCCCCCT GCTGGCTACT TCTCCCAAGT GGCAGAGCAC ATCCGCAAGG 781 CCGGAGGGGT CTTTGTTGCA GATGAGATCC AGGTTGGCTT TGGCCGGGTA GGCAAGCACT 841 TCTGGGCCTT CCAGCTCCAG GGAAAAGACT TCGTCCCTGA CATCGTCACC ATGGGCAAGT 901 CCATTGGCAA CGGCCACCCT GTTGCCTGCG TGGCCGCAAC CCAGCCTGTG GCGAGGGCAT 961 TTGAAGCCAC CGGCGTTGAG TACTTCAACA CGTTTGGGGG CAGCCCAGTG TCCTGCGCTG 1021 TGGGGCTGGC CGTCCTGAAT GTCTTGGAGA AGGAGCAGCT CCAGGATCAT GCCACCAGTG 1081 TAGGCAGCTT CCTGATGCAG CTCCTCGGGC AGCAAAAAAT CAAACATCCC ATCGTCGGGG 1141 ATGTCAGGGG TGTTGGGCTC TTCATTGGTG TGGATCTGAT CAAAGATGAG GCCACAAGGA 1201 CACCAGCAAC TGAAGAGGCT GCCTACTTGG TATCAAGGCT GAAGGAGAAC TACGTTTTGC 1261 TGAGCACTGA TGGCCCTGGG AGGAACATCC TGAAGTTTAA GCCCCCAATG TGCTTCAGCC 1321 TGGACAATGC ACGGCAGGTG GTGGCAAAGC TGGATGCCAT TCTGACTGAC ATGGAAGAGA 1381 AGGTGAGAAG TTGTGAAACG CTGAGGCTCC AGCCCTACCC AACTTTCTTG TACAAAGTtg 1441 gcattataag aaagcattgc ttatcaattt gttgcaacga ac